Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YKYY033 in Chinese Healthy Adult Participants
NCT07786779Phase 1Recruiting
- Sponsor
- Yuekang Pharmaceutical
- Start
- Jul 2026
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in venous thromboembolism (VTE) comparing YKYY033 group with YKYY033 Placebo group (2 arms). Primary endpoints: Adverse Events at 337 days, Serious Adverse Events at 337 days and 1 more. Started Jul 2026; status: recruiting.
02
Drugs
YKYY033
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT07786779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07786779.